Testosterone Therapy Without Injections: The 6 Routes for Women—and the One You Can't Promptly Stop

Testosterone therapy without injections is not a compromise for women. The best-supported route is low-dose transdermal testosterone for an appropriately assessed postmenopausal woman with HSDD. No testosterone product is FDA-approved for women in the US, compounded cream gives up FDA review, and pellets require a procedure and cannot be readily stopped.

This page is for you if—and isn't if

Best for: a woman in perimenopause or postmenopause who does not want recurring injections and needs a clean answer on route, reversibility, FDA status, online access, monitoring, and cost.

Not for you if:

• You're a man researching TRT. This page is about female indications, female dosing constraints, and women's telehealth access.
• You want testosterone mainly for energy, weight loss, muscle gain, anti-aging, or brain fog. The strongest evidence does not support testosterone for those goals. Start with our testosterone for women guide.
• Sex hurts more than desire is absent. Painful sex has FDA-approved needle-free treatments that are not testosterone. Skip to the painful-sex section.
• You want a prescription without an evaluation or monitoring. Testosterone is a Schedule III controlled substance. A legitimate program evaluates you first and does not guarantee a prescription.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The right online HRT provider isn't the same for every woman—it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider—and to flag when online care isn't the right starting point—before your first consult.

The fast answer

Question	Straight answer
Can women use testosterone without injections?	Yes. Low-dose transdermal testosterone is the best-supported route for appropriately assessed postmenopausal HSDD.
Is any testosterone product FDA-approved for women in the US?	No. FDA-approved testosterone products are approved for men, not women.[1]
Which route has the strongest guideline standing?	An FDA-approved male transdermal product used off-label at a female dose, with clinician monitoring.[2][3]
Which route is clearly available through an online menopause provider?	Compounded topical cream through Midi Health, currently advertised in 25 jurisdictions: 24 states plus Washington, DC.[20]
Is there a testosterone patch in the US?	No marketed patch we could verify. Androderm was discontinued by its sole supplier in 2023.[8]
Are pellets truly needle-free?	They avoid recurring self-injection, but insertion is a procedure. They cannot be dialed down after insertion, and removal is not a simple or dependable stop switch.[4]
What should decide the route?	Can you stop the next dose today, and can your clinician monitor and adjust it without pushing levels above the lab's premenopausal range?

For this page, “without injections” means without recurring self-injection. Pellet placement may still involve local anesthetic and an insertion device. Calling pellets “needle-free” without saying “procedure” is marketing, not a full answer.

We built the comparison below from FDA materials, the 2019 Global Consensus Position Statement, the 2021 ISSWSH clinical guideline, ACOG guidance, a 2025 pellet review, DEA and Federal Register records, and six providers' current websites. You should not need eleven tabs to discover the catch after you pay.

---

Which testosterone therapy without injections is best supported for women?

The best-supported route is systemic testosterone absorbed through the skin at a dose intended to keep blood levels inside the laboratory's physiologic premenopausal range. Guidelines give the strongest footing to an approved male transdermal product used cautiously off-label. Compounded cream is easier to obtain online, but it is not FDA-approved and the guideline support is weaker.

The cleanest way to understand this market is to separate route from regulatory status.

Transdermal means the medication crosses the skin into the bloodstream. A gel, cream, solution, or patch can all be transdermal.

FDA-approved means the FDA reviewed a specific finished product for a specific indication and population. A male testosterone gel can be FDA-approved as a product while still being off-label for a woman.

Compounded means a pharmacy prepares the medication for a prescription. A compounded cream may be legal and clinically used, but it is not FDA-approved, and the FDA has not reviewed that exact preparation for safety, effectiveness, or manufacturing consistency before it reaches the patient.^[5]

The six-route ledger

Route	FDA status for a woman	What current guidance says	Can you stop future dosing today?	Current practical access	The catch
1. FDA-approved male gel or solution used off-label	Product approved for men; use in women is off-label	Strongest standing. Global Consensus and ISSWSH allow cautious use of an approved male transdermal product at a female dose with monitoring.[2][3]	Yes	A clinician must prescribe it; it is usually filled at a retail pharmacy	The package, pump, concentration, application site, and label were designed for men, not female dosing. Gel labels also carry a secondary-exposure warning.
2. Compounded cream or gel	Not FDA-approved	Global Consensus leaves a narrow exception where no authorized female equivalent exists and quality standards are met; ISSWSH says compounded products cannot be recommended because product-specific efficacy and safety data are lacking.[2][3]	Yes	Midi Health is the only clearly verified direct program among the six providers reviewed; local clinicians may also prescribe through compounding pharmacies	Concentration, pharmacy, base, beyond-use date, price, and coverage can differ by prescription and pharmacy.
3. Transdermal patch	Historical products were approved for men or authorized outside the US; none is FDA-approved for women	The route fits the transdermal evidence base, but no current US product is available	Yes—remove the patch	No marketed US testosterone patch verified as of August 17, 2026	The most obvious female-friendly format does not exist here.
4. Pellet implant	Testopel is approved for certain male indications; pellets used for women are off-label and often compounded[31]	Preparations that produce supraphysiologic levels, including pellets, are not recommended by Global Consensus. ACOG recommends other preparations because of limited safety data and the pellet not being readily removable.[2][4]	No reliable stop switch	Cash-pay pellet clinics and some in-person practices	It is a procedure, the dose cannot be dialed down after insertion, and the pellet is not readily removable while release continues.
5. Oral or mouth-dissolving products	Approved oral or buccal testosterone products are for men; troches are commonly compounded and not FDA-approved	Oral testosterone is not recommended for women because of adverse lipid effects. Compounded troches do not have a supportive female evidence base.[2]	Yes, for the next dose	Technically prescribable, but not a guideline-supported starting route for women	“Easy to take” does not fix weak female evidence or the oral lipid problem.
6. Nasal gel	FDA-approved for men, not women[33]	No established female dose or efficacy evidence in the major guidance	Yes, for the next dose	No verified menopause-provider pathway in this six-provider check	Three-times-daily male labeling and no established female treatment pathway.[33]

What the guidelines actually agree on

Three statements survive every serious source:

1. The evidence-based indication is narrow. The Global Consensus says the only evidence-based indication is postmenopausal hypoactive sexual desire disorder—low desire that causes distress—after a formal biopsychosocial assessment. The Menopause Society likewise limits its recommendation to select, appropriately screened postmenopausal women with HSDD.^[2][32]
2. The route should be transdermal and the dose physiologic. ISSWSH supports systemic transdermal treatment, with total testosterone used for baseline and monitoring rather than to diagnose HSDD.^[3]
3. Supraphysiologic exposure is the line not to cross. Global Consensus explicitly rejects preparations that produce supraphysiologic concentrations, including pellets and injections.^[2]

The guidelines do not establish one universal target such as 20–80 ng/dL for every woman. Reference ranges vary by assay, age, and laboratory. The operative instruction is to keep the result inside the premenopausal physiologic range for the assay and lab being used, while also watching for androgenic effects.^[3]

That distinction matters. A webpage should not hand you a single magic number and pretend laboratory methods do not exist.

Why “transdermal” matters more than “cream versus gel”

Women ask whether cream or gel is better. Honest answer: the texture is not the decisive part.

The evidence follows systemic absorption through skin at a female-appropriate exposure, not the words “custom,” “bioidentical,” “natural,” or “made for women.” Those words do not change FDA status. They do not turn a compounded preparation into an approved product. They do not create product-specific trial data.

The real questions are:

• Is this a manufactured FDA-approved product used off-label, or a compounded product?
• What exact concentration and dispensed amount am I receiving?
• Which laboratory and assay will be used for monitoring?
• What symptom are we treating?
• When will we reassess?
• Can I stop the next dose immediately if the trade stops making sense?

The gap that explains the whole market

Here is the part providers on both sides tend to crop out:

1. The route with the best evidence is transdermal.
2. The product type with the strongest guideline standing is an FDA-approved male transdermal product used off-label at a female dose.
3. That route is awkward to dose for women and is not the route most online menopause programs sell.
4. The route that is easiest to obtain through a dedicated online menopause program is compounded cream.
5. Global Consensus leaves a narrow compounded exception when no authorized equivalent is available and quality standards are met—but ISSWSH is stricter and says compounded products cannot be recommended because efficacy and safety data are missing.^[2][3]

Read point 5 twice. There is no honest basis for calling compounded cream equivalent to an FDA-approved gel. There is also no honest basis for pretending women have an approved female transdermal product waiting at the pharmacy.

Both facts belong on the same page.

---

Is “needle-free” the same as procedure-free?

No. Creams, gels, pills, nasal products, and troches avoid both self-injection and implantation. Pellets avoid recurring self-injection but require a clinician to insert an implant through a small incision. And no route—topical, oral, nasal, or implanted—is FDA-approved specifically for women in the United States.

Keep three ideas separate and most of the sales pressure disappears:

• No recurring injection: you do not give yourself regular shots.
• Procedure-free: no clinician cuts or inserts anything. Pellets fail this test.
• FDA-approved for women: the FDA approved this exact finished product for women. Every testosterone route fails this test in the US.^[1]

When a clinic says “no more needles,” ask what happens at the appointment. A pellet sales page can technically answer the injection objection while quietly replacing it with an incision, a trocar, a long release period, and no practical dose-reduction switch.

That is not the same bargain as a cream.

---

What is the one rule that should pick your route?

Ask whether you can stop the next dose today. Both Global Consensus and ACOG advise discontinuing transdermal testosterone when there is no meaningful benefit by six months, and long-term safety beyond 24 months remains unestablished. A route that cannot be promptly paused weakens the very trial-and-stop logic the guidance asks clinicians to use.

Testosterone for women should begin as a measured trial, not a lifetime commitment made at checkout.

The usual logic is straightforward:

• define the symptom being treated;
• assess factors that may explain it;
• establish baseline clinical and laboratory information;
• start an appropriate route and dose if the clinician recommends it;
• recheck after initiation and adjust if needed;
• stop by six months if there is no meaningful benefit.^[2][3][6]

Now look at the route through that lens.

Route	What “stop” means	What you cannot instantly undo
FDA-approved male gel used off-label	Do not apply the next dose	Medication already absorbed remains until the body clears it
Compounded cream or gel	Do not apply the next dose	Medication already absorbed remains until the body clears it
Oral product or troche	Do not take the next dose	The most recent dose still has to be metabolized
Nasal gel	Do not use the next dose	The most recent dose still has to be metabolized
Patch, if one existed	Remove it	Medication already delivered remains until cleared
Pellet	There is no dependable pause button	The implant continues releasing while it dissolves; ACOG identifies the pellet not being readily removable as a reason to prefer other preparations[4]

“Stop today” does not mean the hormone vanishes from your bloodstream at 3:00 p.m. It means you control whether another dose enters tomorrow.

That distinction makes the page more accurate without weakening the point. The point is still brutal: topicals let you stop future exposure; pellets do not give you the same control.

Midi makes the same practical argument on its own site even though it sells testosterone. Its public materials say it does not recommend pellets, injections, or troches because they can raise levels excessively and become difficult to bring down, and that pellet treatment cannot be paused after implantation.^[21]

Our editorial conclusion: reversibility is the most important route property for a first trial of an off-label hormone. Convenience is a preference. The ability to stop the next dose is a safety margin.

If you take one thing from this page, take that.

---

Is testosterone FDA-approved for women—and what does off-label mean?

No testosterone product is FDA-approved for women in the United States. FDA's current testosterone information says approved products are for men with specific forms of low testosterone associated with a medical condition. A woman therefore receives either an FDA-approved male product off-label, a compounded preparation that is not FDA-approved, or an off-label implant.

Off-label means a licensed clinician prescribes an FDA-approved product outside the population, indication, dose, or use described in its approved label. It is legal and common. It is not proof that a treatment is wrong.

It also is not a magic eraser. The fact that prescribing is lawful does not mean the FDA reviewed the product for a woman's dose, a woman's indication, or a woman's long-term outcomes.

What you may be offered	Is the finished product FDA-approved?	Is it approved for women?	Practical meaning
AndroGel, Testim, Vogelxo, Fortesta, or another manufactured male topical product	Yes	No	Standardized manufactured product and label; female use is off-label and requires product-specific dosing instructions from the prescriber
Compounded testosterone cream or gel	No	No	Pharmacy-prepared for the prescription; FDA has not approved that exact finished preparation
Testosterone pellet used in a woman	Testopel is approved for male indications; many women's pellets are compounded[31]	No	Off-label or compounded, plus a procedure and poor reversibility
Supplement-store “testosterone booster”	No—it is not prescription testosterone	No	Not a substitute for prescribed testosterone and not part of the guideline-supported route decision

Testosterone is a Schedule III controlled substance

Testosterone is listed by the DEA as a Schedule III controlled substance.^[7] That means lawful care requires an appropriately licensed prescriber authorized to prescribe controlled substances, a valid prescription, and compliance with federal and state rules.

That is why testosterone access does not behave exactly like estradiol or progesterone access. It can affect visit requirements, quantity, refills, pharmacy handling, telemedicine policy, and whether a general marketplace provider will prescribe it.

Anyone offering “testosterone” with no prescriber, no evaluation, and no controlled-substance process is not offering legitimate prescription care.

---

What is the difference between a men's gel and a women's compounded cream?

Gel and cream describe texture, not regulatory status. A manufactured testosterone gel is FDA-approved for men and may be used off-label in women. A compounded cream is prepared for a prescription and is not FDA-approved. The real trade is approved manufacturing and printed labeling versus female-practical dispensing and easier specialized online access.

This is where the money is, so this is where the language has to stay clean.

What you get with an FDA-approved male gel or solution

You get a manufactured product covered by an approved application, with a standardized concentration, a published label, defined packaging, and product-specific instructions.

You also get a container and concentration built for a man. The labeled application site, pump actuation, packet size, and transfer precautions were not designed around a woman's off-label dose.

That does not make the route unusable. It makes the prescriber's exact instructions non-negotiable. Do not improvise a dose, share medication, use another person's product, or copy conversion math from a webpage.

Retail cost cannot be responsibly reduced to one “monthly” number here. It depends on the exact product, package, pharmacy, insurance decision, and how the prescription is written. A package price is not automatically a woman's monthly cost. Confirm the dispensed price with the pharmacy before treatment.

What you get with a compounded cream

You get a preparation that can be dispensed at a concentration practical for a female prescription. With a structured program, you may also get an intake evaluation, baseline testing, follow-up testing, and dose adjustment.

What you give up is FDA approval of the exact finished preparation. Compounded products are not interchangeable by assumption. The pharmacy, concentration, vehicle, dispenser, beyond-use date, and handling instructions matter.

The prescription label should identify what was dispensed. The gap in Midi's public material is not that a dispensed bottle has no strength—it is that Midi does not publish the program's concentration online, so you cannot compare that number before the visit. Ask for it.

Side by side

Decision point	FDA-approved male gel used off-label	Compounded cream or gel
FDA status	Approved finished product—for men	Not FDA-approved
Female use	Off-label	Compounded for the prescription
Concentration	Published on the manufacturer label	Must be confirmed from the prescription and dispensed label; may vary
Female-practical dispensing	Often awkward	Usually easier to dispense at a female-appropriate concentration
Guideline standing	Strongest available footing when cautiously dosed and monitored[2][3]	Global Consensus allows a narrow no-equivalent exception; ISSWSH does not recommend compounded products[2][3]
Transfer issue	Product label carries secondary-exposure precautions	Transfer precautions must come from the prescriber and pharmacy for that preparation
Insurance	May be covered, but off-label coverage varies by plan	Coverage varies generally; Midi says its testosterone medication is not covered[22]
Public price	Must be checked for the exact prescription and pharmacy	Midi advertises starting at $100 for a 90-day supply, medication only[19]
Stop future dosing	Yes	Yes
Where you get it	Prescriber plus retail pharmacy	Compounding pharmacy through a prescriber or program

The part we'd rather not tell you

Here it is, because you would find out eventually and we would rather you heard it from us.

The route with the strongest guideline and regulatory footing is the one we earn nothing from—and it is not the route Midi sells.

An FDA-approved male transdermal product used off-label at a female dose is the route to ask about when standardized manufacturing and a published product label matter most to you. Midi's testosterone program uses compounded cream instead.^[20]

That is a real damaging admission, not a fake “it isn't perfect” line.

If FDA-approved manufacturing is your priority, ask a menopause or sexual-medicine clinician about an approved male transdermal product used off-label. Start with our testosterone cost guide and take the request to a clinician who is comfortable treating HSDD.

Midi wins a different argument: female-practical dispensing, a dedicated online workflow, baseline labs, repeat testing at about four to six weeks, and ongoing follow-up in the jurisdictions it currently serves.^[20]

What Midi does not win is equivalence. A compounded cream does not become equivalent to an FDA-approved gel because the products share a hormone name. One has an approved finished-product application; the other does not.

Which trade fits you depends on what you need most:

• Choose the conversation about a manufactured male gel when published labeling and FDA-approved manufacturing are your first priority.
• Consider the compounded-program conversation when online access and female-practical dispensing matter more—and you accept the loss of FDA review for that exact preparation.

Neither route removes the need for evaluation, monitoring, and a six-month stop rule if there is no meaningful benefit.

---

Are testosterone pellets really a needle-free option?

Pellets avoid recurring self-injection, but they are not procedure-free and they are not readily reversible. ACOG recommends other preparations because of limited safety data and the pellet not being readily removable. Global Consensus rejects preparations that produce supraphysiologic levels, including pellets, and a 2025 review found a sparse, heterogeneous evidence base.

We should be fair before we are severe. Pellet clinics are solving a real adherence problem.

Why women choose pellets

Nothing to apply every morning. Nothing to transfer to a partner or grandchild. No pump, packet, drying time, or daily reminder. A few appointments a year instead of a daily habit.

That convenience is real. Pretending otherwise makes the rest of the criticism weaker.

What that convenience costs

Once the pellet is inserted, you cannot reduce tomorrow's dose. ACOG's language is blunt enough without embellishment: limited safety data and the pellet not being readily removable are reasons to recommend other preparations.^[4]

A 2025 review assembled decades of pellet pharmacokinetic reports. The often-cited peak concentrations included approximately 144, 250, 257, and 299 ng/dL in different studies, with substantial between-woman variability.^[9]

Study summarized in the 2025 review	Pellet exposure reported	Reported testosterone result
Thom, 1981	100 mg	Approximately 144 ng/dL at about four weeks
Kapetanakis, 1982	75 mg	Mean approximately 250 ng/dL
Buckler, 1998	100 mg	Approximately 257 ng/dL at about one month
Glaser, 2013	Weight-based dosing	Approximately 299 ng/dL at four weeks, with wide between-patient variation

Those numbers are not a clean head-to-head trial. The studies used different eras, assays, designs, populations, and dosing. They should not be turned into a fake precision chart that says every modern pellet produces the same peak.

What they do show is the problem guidelines are reacting to: pellet exposure can be high, variable, and impossible to dial down after insertion.

The fair hearing

The pellet literature is not empty.

• The 2025 review identified one randomized pellet trial and a number of observational studies and practice-based cohorts.^[9]
• A 2025 clinical-practice study of lower-dose pellets reported low observed rates of acne and facial hair and no erythrocytosis signal in its cohort.^[10]
• Some long-running pellet cohorts report symptom improvement and reassuring observational outcomes.

Those findings deserve to be reported. They also do not erase the design limitations, selection bias, conflicts of interest in parts of the literature, lack of robust long-term comparative evidence, or the basic reversibility problem.

The honest conclusion is not “pellets are proven dangerous.” The honest conclusion is “safety is not established well enough to override current guidance, and the route gives up control after insertion.”

Where we land

Pellets are a poor first route for a woman who has never learned how she responds to testosterone.

That is an editorial conclusion based on three verified facts:

1. treatment should stop if there is no meaningful benefit by six months;
2. preparations producing supraphysiologic levels are not recommended;
3. a pellet cannot be dialed down after insertion and is not readily removable.^[2][4][6]

A woman still considering pellets after a successful, monitored topical trial should know exactly what she is choosing against: current guideline preference, easy dose adjustment, and the ability to stop the next dose.

Do not let “only a few appointments a year” end that conversation early.

---

Why is there no testosterone patch for women in the US?

There is no marketed testosterone patch in the United States as of August 17, 2026. Androderm, the sole US testosterone patch, was discontinued by its only supplier in 2023. Intrinsa delivered testosterone through a patch designed for women in Europe, but its European authorization was withdrawn in 2012 and it was never FDA-approved for women here.

A patch sounds almost designed to resolve this entire article.

Fixed delivery. No measuring. No open gel sitting on skin. Remove it when you want to stop.

It is also unavailable.

ASHP's drug-shortage record says Allergan/AbbVie discontinued Androderm in 2023 and was the sole supplier. The record lists no available presentations.^[8]

Intrinsa was a female-specific patch that delivered 300 micrograms over 24 hours. It received European authorization for a narrow population, and the European Commission withdrew that authorization in 2012.^[11] It never became an FDA-approved product for women in the United States.

That leaves a strange market:

• the evidence base is heavily transdermal;
• a patch is the most obvious controllable transdermal format;
• no female patch is approved here;
• no male patch remains on the US market;
• women are left choosing between an awkward male gel and compounded topical products.

The Global Consensus estimates the average benefit for postmenopausal HSDD at roughly one additional satisfying sexual event per month, plus improvements in desire and distress measures.^[2] That is a moderate benefit, not a personality transplant. It is also enough for major societies to support a carefully selected, monitored trial.

The route with the cleanest physical logic is the route you cannot buy. That is not a reason to pretend a compounded cream is approved. It is the reason the compounded market exists.

---

Can women take testosterone pills, nasal gel, or troches instead?

These routes avoid recurring injections, but none is a strong starting option for women. Global Consensus recommends against oral testosterone because of adverse lipid effects. Nasal gel is approved and labeled for men with no established female treatment pathway. Troches are compounded, not FDA-approved, and lack a guideline-supported female evidence base.

Oral testosterone

Several prescription oral testosterone products exist for men. That does not create a female indication.

The Global Consensus specifically says oral testosterone therapy is associated with adverse lipid profiles and is not recommended for women.^[2]

“A pill is easier” is true. It is not a complete decision rule.

Buccal products and troches

An FDA-approved buccal testosterone product exists for men.^[1] Compounded troches and lozenges also circulate through hormone clinics.

Do not let all mouth-dissolving products blur together:

• an approved male buccal product is still off-label for a woman;
• a compounded troche is not FDA-approved;
• neither has the female evidence footing of low-dose transdermal treatment.

Midi publicly says it does not recommend troches, injections, or pellets because levels can rise too high and become difficult to bring down.^[21] A troche can be skipped the next day; it is not physically irreversible like a pellet. The concern is exposure and evidence, not an implant that remains in the body.

Nasal gel

Natesto is a testosterone nasal gel labeled for men.^[33] The major women's guidance does not establish a female dose, efficacy claim, or monitoring pathway for it.

It also requires three-times-daily dosing under the male label.^[33] That is a lot of friction for a route with no established female advantage.

Which is why the answer keeps landing in the same place: skin, a female-appropriate exposure, monitoring, and the ability to stop future dosing.

---

Can testosterone cream or gel transfer to a partner or child?

Yes, topical testosterone can transfer through skin contact. Current testosterone-gel labeling warns about secondary exposure to women and children and instructs patients to wash their hands, let the product dry, cover the site, and wash the site before anticipated skin-to-skin contact. Female-dose-specific transfer timing is not established in the male product label.

This is one of the two fears that repeatedly stop women from even asking about the route.

It deserves a real answer, not “just wash your hands.”

What the FDA-approved gel label says

Current testosterone-gel labeling describes reported virilization in children after secondary exposure. Reported signs have included genital enlargement, early pubic hair, increased erections or libido, aggressive behavior, and advanced bone age. Some findings did not fully reverse after exposure ended.^[12]

The label's core precautions are:

• wash hands with soap and water immediately after application;
• allow the application site to dry;
• cover the site with clothing;
• wash the site before anticipated skin-to-skin contact;
• keep children and women away from unwashed or uncovered application sites.^[12]

The label was written for male users, so it frames women and children as the exposed people. When a woman is the patient, the transfer principle does not disappear. The treated patient becomes the potential source.

What the label does not answer for a woman

The approved male label does not tell a female off-label patient:

• whether the lower female dose changes the safe-contact interval;
• whether a compounded cream behaves like the labeled gel;
• whether thigh, vulvar, abdominal, arm, or shoulder application changes practical transfer risk;
• how the cream base affects drying or residue;
• what to do when daily caregiving makes site separation difficult.

We looked for a universal female-dose answer. It is not there.

That is a gap—not permission to invent reassurance.

The 2025 and 2026 labeling changes did not erase transfer precautions

FDA removed cardiovascular-risk language from testosterone boxed warnings in 2025 after reviewing the TRAVERSE trial and added class-wide blood-pressure information.^[13] FDA made additional label updates in 2026.^[1]

Those actions did not turn topical transfer into an obsolete issue. Current gel labeling still carries secondary-exposure precautions.^[12]

Ask this before the medication ships:

Where exactly should I apply this product relative to skin contact with my partner, child, or grandchild; how long should I keep the area covered; and are those instructions specific to my concentration and cream base?

Get the answer in writing. A portal message counts.

---

What side effects happen at a physiologic female dose—and what remains unknown?

Randomized evidence at physiologic female exposure shows more acne and hair growth, while trials did not detect higher rates of alopecia, voice change, or clitoral enlargement versus comparators. That reassurance applies to studied, monitored doses—not supraphysiologic exposure. Long-term safety beyond 24 months remains unestablished, and higher-risk women were underrepresented.

The large 2019 systematic review and meta-analysis found:

• acne was more likely with testosterone: relative risk 1.46;
• hair growth was more likely: relative risk 1.69;
• trials did not record higher rates of alopecia, clitoromegaly, or voice change versus comparator;
• no serious adverse event was more frequent in the pooled randomized data.^[14]

That is not the same as saying irreversible androgenic effects can never happen. It means the controlled trials at physiologic exposure did not detect an increase in those outcomes.

Dose and route matter. A reassurance earned by monitored transdermal trials cannot be pasted onto a pellet exposure that pushes a patient above her assay's premenopausal range.

What is genuinely unknown

• Safety beyond 24 months: the Global Consensus says physiologic-dose safety data are not available beyond two years.^[2]
• Higher cardiometabolic risk: the randomized trials largely excluded high-risk women, limiting how broadly short-term reassurance can be applied.^[2]
• Breast cancer history: women with prior breast cancer were excluded from the key trials; caution is recommended for hormone-sensitive disease.^[2]
• Long-term breast and cardiovascular outcomes: the available trials were not built to settle those questions.
• Product-specific compounded safety: a guideline evidence base for transdermal testosterone does not equal product-specific proof for every compounded cream.

What testosterone is—and is not—proven to do

Goal	What the evidence supports
Postmenopausal HSDD after biopsychosocial assessment	The only evidence-based indication identified by Global Consensus; average benefit is moderate[2]
General energy or fatigue	Not an established indication
Weight loss or metabolism	Not an established indication
Brain fog, memory, or cognitive protection	Insufficient evidence
General wellbeing	No demonstrated benefit in the consensus evidence
Depressed mood	No established treatment benefit
Bone density	No demonstrated benefit at 12 months in the available evidence
Muscle mass or strength	No significant benefit established at physiologic doses in the available trials
Premenopausal sexual dysfunction	Insufficient evidence for a recommendation

If you came here for energy and focus, the endpoints you care about are not the endpoints with the strongest evidence.

That does not mean your fatigue is imagined. It means testosterone should not become the answer before someone looks at sleep disruption, hot flashes, iron status, thyroid disease, medication effects, depression, pain, relationship factors, and other causes that may actually match the symptom.

Does that sound like your situation? Use Find My HRT Path to separate desire, pain, sleep, energy, insurance, state, and risk-history branches before you book with a testosterone program.

---

If sex hurts, is there an FDA-approved needle-free option that is not testosterone?

Yes. Painful sex from genitourinary syndrome of menopause has FDA-approved needle-free treatments, including local vaginal estrogen products and vaginal prasterone.^[5][15] Pain and absent desire are different problems. Treating the pain first may change the desire problem, while systemic testosterone remains an off-label option only for a narrow HSDD use case.

A lot of women arrive at testosterone through the wrong door, and it costs them months.

Three problems can sound like one sentence:

• It hurts. Dryness, burning, tearing, or urinary symptoms point toward genitourinary syndrome of menopause.
• I want to, but my body is not responding. That is an arousal problem.
• I do not want to, and the loss of desire bothers me. That is the HSDD branch testosterone was studied for.

When pain is driving avoidance, treating “desire” first can mean treating the wrong end of the problem.

Vaginal prasterone—Intrarosa—is FDA-approved for moderate to severe dyspareunia due to menopause.^[15] FDA-approved local vaginal estrogen options are also available for menopausal vulvovaginal symptoms. Those products are not the same thing as systemic DHEA or testosterone.

Is Addyi now an FDA-approved option for some postmenopausal women?

Yes. FDA expanded Addyi's indication in December 2025, so the old premenopausal-only description is no longer correct.

The current Addyi label indicates flibanserin for women younger than 65 with acquired, generalized HSDD, and the label includes postmenopausal efficacy and safety data.^[16]

Vyleesi remains an injection indicated for premenopausal women with acquired, generalized HSDD.^[17]

So the current map is:

Problem	FDA-approved needle-free option?	Important limit
Menopausal painful sex from vulvovaginal atrophy/GSM	Yes—local vaginal estrogen products and vaginal prasterone	Product selection depends on history and clinician evaluation
Acquired, generalized HSDD in a woman under 65	Addyi is FDA-approved and needle-free	It has its own contraindications, interaction risks, administration rules, and stop criteria; it is not testosterone
HSDD in a premenopausal woman who accepts an injection	Vyleesi is FDA-approved	It is not indicated for postmenopausal women
Testosterone for a woman	No FDA-approved product	Any use is off-label, compounded, or both

That does not make Addyi the automatic answer. It means a woman under 65 with acquired, generalized HSDD now has an FDA-approved needle-free prescription option that deserves to be discussed before a webpage tells her testosterone is the only path.

DHEA is not interchangeable with testosterone

DHEA is a precursor hormone. Systemic DHEA and vaginal prasterone are not the same treatment decision.

Global Consensus says systemic DHEA cannot be recommended for HSDD in postmenopausal women with normal adrenal function because it does not significantly improve libido or sexual function.^[2]

Winona offers prescription DHEA and does not prescribe testosterone. Its own marketing frames DHEA as a safer alternative with similar benefits.^[23] That is Winona's provider claim, not the conclusion of the Global Consensus.

Vaginal prasterone is a locally administered FDA-approved product for menopausal dyspareunia. Systemic DHEA sold as a testosterone alternative is a different route, product, indication, and evidence question.

Do not let anyone hand you one and call it the other.

---

Which online providers prescribe testosterone without injections?

Among six online women's-health providers checked on August 17, 2026, Midi Health is the only one with a clearly verified direct testosterone program. It offers compounded topical cream in 25 listed jurisdictions—24 states plus Washington, DC. Inner Balance's own pages conflict about testosterone, so we do not count Oestra as a verified testosterone option.

We asked the same question across all six provider sites, labeled an absence as an absence, and left first-party contradictions visible instead of choosing the answer that made a cleaner table.

Provider-stated versus verified

Provider	Provider-stated position	What The HRT Index verified	Route	Checked
Midi Health	Offers a women's testosterone program in “25 states”	Clearly verified. Its site describes compounded topical cream, baseline labs, a second visit for many patients, repeat testing at 4–6 weeks, and later monitoring. Its jurisdiction count is 24 states plus DC.[20]	Compounded topical cream	Aug. 17, 2026
Winona	Does not prescribe testosterone; offers DHEA instead	Confirmed. Winona's FAQ says it does not prescribe testosterone.[23]	No testosterone	Aug. 17, 2026
Sesame Care	Online providers do not prescribe controlled substances, including testosterone	Confirmed. This is stated in Sesame's prescription-refill and menopause materials.[24]	No online testosterone	Aug. 17, 2026
Hers	Sells hormone testing, including free testosterone	No testosterone treatment pathway found. That is an absence, not a direct company statement that treatment will never be offered.[25]	Testing only in this check	Aug. 17, 2026
Alloy	Does not offer testosterone therapy at this time	Confirmed. Alloy's current knowledge-base material states this directly.[26]	No testosterone	Aug. 17, 2026
Inner Balance / Oestra	Main treatment page says Oestra has no added testosterone; another live page says Oestra delivers estradiol, progesterone, and testosterone vaginally	Internally inconsistent. We do not count it as a verified testosterone option until the company resolves the contradiction.[27][28]	Unclear from first-party pages	Aug. 17, 2026

That Inner Balance row is not a gotcha. It is exactly why provider verification has to be page-by-page rather than logo-by-logo.

Its main treatment page says Oestra does not contain added testosterone. A separate live education page says Oestra delivers estradiol, progesterone, and testosterone vaginally. Other current pages describe Oestra as estradiol plus progesterone.^[27][28]

A reasonable reader cannot resolve the formula from those pages. Until Inner Balance publishes one consistent answer, do not choose Oestra because you believe it is a testosterone product. Ask for the exact prescribed ingredients in writing.

What Hers's lab range does—and does not—tell you

Hers publishes a free-testosterone reference range of 0.0–4.2 pg/mL for women and offers testing.^[25]

A low-end reference value of zero does not mean a woman can be diagnosed with HSDD from a blood number. Global Consensus and ISSWSH say no testosterone cutoff separates women with and without sexual dysfunction, and total testosterone is used as a baseline and monitoring tool—not as the diagnostic test for desire.^[2][3]

Testing can be clinically useful when a clinician is investigating androgen excess or monitoring treatment.^[2][3] It is not a lab-ticket shortcut into testosterone therapy.

What Midi's program actually includes

Item	Verified provider-stated detail
Product	Compounded low-dose testosterone cream[19][20]
Jurisdictions	Arizona, California, Colorado, Delaware, Florida, Iowa, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Nevada, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia, Washington, and Washington, DC—24 states plus DC[20]
Medication price	Starts at $100 for a 90-day supply; this is a starting medication price, not an all-in care price[19]
Self-pay visits	Midi currently publishes $250 initial and $150 continued-care self-pay visit prices; insurance coverage varies by plan[29]
Process	Video evaluation, laboratory review, then a second visit for many women before prescribing[20]
Monitoring	Baseline testing, repeat around 4–6 weeks, then clinician-directed follow-up that may be every 6–12 months[20]
Insurance	Midi says the testosterone medication is not covered; visits may be billed to eligible insurance plans, subject to plan rules[22][29]
Medicare/Medicaid	Midi says it is not enrolled with Medicare, Medicaid, or Medi-Cal for these services and publishes specific limits for beneficiaries[29]
Platform pharmacy disclosure	Midi's current terms identify Precision Compounding Pharmacy as a pharmacy available through the platform; confirm whether it will fill your testosterone prescription[30]
Publicly missing	Program concentration, product-specific transfer interval, and the exact dispensed price for an individual prescription
Cancellation	For subscription products covered by Midi's general terms, cancellation must occur at least two days before renewal; cancellation takes effect at the end of the current period and partial-period refunds generally are not offered. Confirm that these terms govern your exact prescription at checkout.[30]

Four inconsistencies to ask Midi about before paying

Midi's current pages are unusually transparent about access and process. They are not perfectly consistent.

1. Application site varies across pages. We found inner thigh in cost content and upper arms, shoulders, or abdomen in a treatment article. Follow the prescription and pharmacy label, not a blog post.^[21][22]
2. Public symptom claims run wider than the guideline evidence. Midi markets support for libido, energy, mood, strength, cognition, and brain fog, while Global Consensus recognizes postmenopausal HSDD as the only evidence-based indication.^[2][20]
3. The program concentration is not published. Ask for the exact concentration, dispenser output, and pharmacy before the medication ships.
4. The public timeline varies. One part of the testosterone page says a clinician may reconsider after 12 weeks; its FAQ also says stopping may be considered by six months. The guideline-compatible rule is to reassess throughout and stop by six months if there is no meaningful benefit.^[20]

Those are not reasons to pretend the program does not exist. They are the questions that separate a useful provider comparison from a referral button.

One provider-hosted patient account

“My sex drive and ability to orgasm decreased through perimenopause. Testosterone changed that. I'm back to my baseline level of wanting to have sex.” — Kimberly S., published by Midi Health^[20]

Provider-hosted individual experience. Not independently verified by The HRT Index. Not evidence of safety or effectiveness and not a promise of your result. We include it because it is real, attributable, and labeled—not because a testimonial can prove a medical claim.

The decision

Midi is the only clearly verified direct online testosterone program in this six-provider check. It uses the route class the evidence favors—transdermal—but the product is compounded, not FDA-approved, and the public program claims are broader than the consensus indication.

That is the whole answer, not the sales answer.

Does the compounded trade fit what you are looking for? Check Midi's current testosterone availability and evaluation process. A visit is an evaluation, not a guaranteed prescription.

Affiliate disclosure: The HRT Index may earn a commission if you start care through an eligible provider link. It does not change your price. Commercial relationships do not change FDA status, route evidence, provider availability, or the contradictions reported above.

---

What does needle-free testosterone therapy cost?

The only clean current online medication price in this provider check is Midi's provider-stated starting price of $100 for a 90-day compounded-cream supply. That is not the all-in cost. Visits, baseline labs, repeat labs, shipping, refills, and insurance rules can be separate. A manufactured gel's retail cost must be checked for the exact prescription and pharmacy.

The cheapest package is not automatically the cheapest care.

The verified cost stack

Cost component	What is currently published	What you still have to confirm
Midi initial visit	$250 self-pay, or applicable eligible-insurance cost sharing[29]	Network status, deductible, copay, and whether your plan covers this visit
Midi continued-care visit	$150 self-pay, or applicable eligible-insurance cost sharing[29]	How many visits will be required before and after prescribing
Midi compounded cream	Starts at $100 for a 90-day supply[19]	Exact dispensed price, concentration, quantity, shipping, renewal interval, and whether a subscription is required
Baseline laboratory testing	Required in Midi's process[20]	Lab panel, laboratory, insurance billing, and cash price
Follow-up laboratory testing	Typically around 4–6 weeks, then clinician-directed[20]	Frequency, panel, and who pays
Manufactured male gel used off-label	No single valid page-wide price	Exact product, package, pharmacy cash price, insurance decision, prior authorization, and days supplied
Cancellation	Midi's general subscription terms require cancellation at least two days before renewal for covered subscription products[30]	Whether those terms apply to your exact prescription and what happens to an order already processing

Why this page does not publish one retail gel price

Live discount feeds can show low generic-gel and AndroGel prices, but those snapshots are not a reliable page-wide answer.

A coupon number is not a manufacturer or pharmacy quote for a defined prescription, package, location, and fill date. It also encourages a false comparison between package price and a woman's monthly cost.

A medically responsible page should not publish a low coupon number as though it is the price a woman will pay. Get the prescribed National Drug Code, quantity, days supplied, and pharmacy quote first.

The question that prevents the surprise bill

Ask for one number:

What is my expected first-90-day total—including every visit, laboratory charge, medication shipment, and required follow-up—not just the cream's starting price?

Then ask whether the answer assumes that insurance accepts the claim.

No fake “starting at” arithmetic. No converting a man's packet into a woman's monthly estimate. No borrowing a partner's gel.

Using someone else's testosterone is unsafe, violates the prescription, and involves a Schedule III controlled substance.

If daily, adjustable, stoppable cream is the trade you accept, see Midi's current program details before booking. Bring the questions in the checklist below.

---

Can testosterone still be prescribed by telehealth without an in-person visit in 2026?

In many cases, yes—under the current federal temporary extension, a DEA-registered practitioner may prescribe Schedule II–V controlled medications through qualifying telemedicine without a prior in-person medical evaluation through December 31, 2026. Federal flexibility does not override state law, licensing, clinical judgment, pharmacy policy, or a provider's own restrictions.

Testosterone is the menopause-care outlier here because it is scheduled while estradiol and progesterone are not.

DEA and HHS published the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 Fed. Reg. 61301, effective January 1 through December 31, 2026.^[18]

That rule is why a qualifying controlled-substance prescription can still begin through telemedicine without a prior in-person evaluation under the federal temporary framework.

It does not guarantee that:

• your state permits the encounter;
• the clinician is licensed where you are physically located;
• the provider offers testosterone;
• the clinician believes it is appropriate;
• the pharmacy will fill that prescription;
• the same process will remain after December 31, 2026.

The permanent telemedicine framework was not finalized when this page was verified.

Do not let a provider turn that deadline into fake urgency. The temporary rule has been extended repeatedly. Nobody can promise what comes next.

Ask this instead:

If federal or state telemedicine rules change, what happens to my next refill, and do you have an in-person continuity plan?

A serious controlled-substance program should have an answer before the rule changes, not after your cream runs out.

---

Who should not start with online testosterone care?

Online care is not the right first stop when symptoms need a physical examination, the clinical picture is complex, laboratory follow-up is not realistic, or the goal falls outside the evidence. A telehealth program should be willing to lose the prescription when an in-person evaluation is the safer or more complete starting point.

Start in person—or with the clinician already managing your case—when:

• you are pregnant, trying to conceive, or breastfeeding;
• you have unexplained rapid facial or body hair growth, voice change, severe acne, scalp hair loss, or other new signs of androgen excess;
• you have unexplained bleeding, a genital lesion, a lump, severe pain, or symptoms that require an examination;
• you have a hormone-sensitive cancer history or another risk history that needs specialist coordination;
• you cannot complete baseline and follow-up laboratory work;
• you want testosterone for athletic performance, body composition, weight loss, anti-aging, or a vague “optimization” target;
• pain, dryness, tearing, or urinary symptoms are the dominant sexual problem;
• medication effects, depression, relationship distress, sleep disruption, or another modifiable cause may better explain the loss of desire.

This is not a complete contraindication list. It is a routing list.

A good online program does not simply ask, “Can we ship this?” It asks, “Is this the right problem, the right route, and the right setting?”

---

What should you ask before you pay for testosterone without injections?

Ask for the exact product, pharmacy, concentration, treatment target, monitoring plan, total cost, transfer instructions, six-month stop rule, refill process, and cancellation terms. None of those details should remain implied. A portal message, prescription label, checkout screen, or written care plan gives you something you can verify later.

Print this section or save it to your phone.

1. Which exact product am I receiving: an FDA-approved male gel used off-label, or a compounded cream?
2. If it is compounded, which pharmacy makes it, and is the pharmacy licensed to dispense to my state?
3. What is the exact concentration, dispenser output, and prescribed amount?
4. What diagnosis or symptom are we treating, specifically?
5. What should improve if treatment works, and how will we measure that?
6. Which tests are required before treatment, at 4–6 weeks, and after the dose is stable?
7. What is my expected first-90-day total, including visits, labs, medication, shipping, and follow-up?
8. Where do I apply it, how long must it dry or stay covered, and what are the transfer precautions for my exact preparation?
9. What is my reassessment date, and will we stop by six months if there is no meaningful benefit?
10. How do controlled-substance refills work, and what visit is required for renewal?
11. What happens if federal or state telemedicine rules change?
12. How do I cancel, how much notice is required, and what happens to a prescription already processing?

Question 9 is the one almost nobody asks. Put the date on the calendar before the first dose.

Route & Reversibility Card

Write this down before starting	Your answer
Exact route and product
FDA-approved male product used off-label, or compounded?
Pharmacy and concentration
Application site and transfer instructions
Baseline lab date
First repeat lab date
Symptom being treated
What counts as meaningful benefit
Six-month stop date
First-90-day total cost
Refill visit requirement
Cancellation notice period

This card forces the details that actually decide the route into one place: your product, state, pharmacy, concentration, price, lab dates, transfer instructions, and stop date. Print the page. No email required. Nothing stored.

---

What did The HRT Index actually verify?

The HRT Index Verification Standard reads every published price, keeps FDA-approved and compounded options separate, verifies state availability and insurance, checks provider-stated details against live first-party pages, dates every price and availability claim, and reports contradictions instead of silently choosing the more convenient version. Top providers are re-checked monthly and the full roster quarterly. Providers are evaluated on clinical legitimacy, care quality, medication fit, price transparency, and access.

Checked on August 17, 2026

• FDA's current testosterone information and class-wide labeling actions;
• current testosterone-gel secondary-exposure labeling;
• the 2019 Global Consensus Position Statement;
• the 2021 ISSWSH clinical practice guideline;
• ACOG's pellet guidance and six-month discontinuation recommendation;
• the 2019 systematic review and meta-analysis of testosterone for women;
• the 2025 review of testosterone pellets in women;
• ASHP's Androderm discontinuation record;
• the current Addyi, Vyleesi, and Intrarosa labels;
• DEA's Schedule III listing for testosterone;
• the Fourth Temporary Extension in the Federal Register;
• Midi, Winona, Sesame Care, Hers, Alloy, and Inner Balance first-party pages;
• Midi's current price, visit process, monitoring language, self-pay visit rates, and general subscription terms.

What we could not verify—and did not guess

• Midi's publicly undisclosed testosterone concentration;
• whether Precision Compounding Pharmacy—the pharmacy named in Midi's terms—will fill every individual testosterone prescription;
• an individual's dispensed price above the published starting figure;
• whether every Midi testosterone order is governed by the same subscription terms;
• a direct Hers statement ruling out future testosterone treatment—we found testing and no treatment pathway;
• one consistent Inner Balance answer on whether Oestra contains testosterone;
• first-party pellet prices across a comparable national set of clinics;
• a universal female transfer interval for every gel and compounded cream;
• a single universal testosterone target range that overrides laboratory and assay differences.

We do not refresh “Last verified” because a comma moved. The date changes when the commercial and medical claims are rechecked.

---

Frequently asked questions

Is testosterone therapy without injections as effective as injections for women?

The evidence base for women is primarily transdermal, not injectable. Global Consensus does not recommend preparations that produce supraphysiologic concentrations, including injections and pellets. Going without recurring injections is not a downgrade; low-dose transdermal therapy is the guideline-supported route.

What is the best-supported form of testosterone for women?

A government-approved male transdermal product used cautiously off-label at a female dose has the strongest guideline standing. A compounded topical product is easier to access through some women's-health programs, but it is not FDA-approved and ISSWSH does not recommend compounded products because product-specific efficacy and safety data are lacking.

Is there a testosterone patch for women in 2026?

No. There is no marketed testosterone patch in the United States as of August 17, 2026. Androderm was discontinued by its sole supplier in 2023. Intrinsa was a female-specific European patch, but its authorization was withdrawn and it was never FDA-approved for women in the US.

Are testosterone pellets safe for women?

Long-term safety has not been established well enough to override current guidance. ACOG recommends other preparations because of limited safety data and the pellet not being readily removable. Global Consensus rejects preparations that produce supraphysiologic concentrations, including pellets. Observational studies report benefits and some reassuring findings, but the evidence is heterogeneous and does not solve the reversibility problem.

Can testosterone cream be stopped immediately?

You can stop future dosing immediately by not applying the next dose. Medication already absorbed still has to clear from the body. That is still a major reversibility advantage over a pellet, which continues releasing after insertion.

Is compounded testosterone cream FDA-approved?

No. It is pharmacy-prepared for a prescription and may be lawful, but the FDA has not approved that exact finished preparation for safety, effectiveness, or manufacturing consistency. It should never be described as equivalent to an FDA-approved testosterone product.

Can a woman use her partner's testosterone gel?

No. It is prescribed to another person at a different dose, carries a transfer warning, and is a Schedule III controlled substance. A woman considering testosterone needs her own evaluation, prescription, instructions, and monitoring plan.

Does testosterone cause facial hair or a deeper voice in women?

At physiologic exposure in randomized trials, acne and hair growth were more common. The trials did not detect higher rates of voice change, alopecia, or clitoral enlargement versus comparators. That does not prove those effects cannot occur—especially with excessive exposure—and long-term safety remains uncertain.

Can you get testosterone prescribed online without an in-person visit?

Often, yes, under current federal telemedicine flexibility through December 31, 2026, when all other conditions are met. State law, clinician licensing, provider policy, pharmacy policy, and clinical judgment still apply. No legitimate platform guarantees a prescription.

Does insurance cover compounded testosterone cream?

Coverage varies across the market. Midi specifically says its testosterone medication is not covered, although eligible visits may be billed to insurance. Confirm the exact medication, pharmacy, claim pathway, and out-of-pocket cost before the prescription is sent.

How long should a woman stay on testosterone?

Start with a defined trial. If there is no meaningful benefit by six months, guidance says to stop. If treatment continues, regular clinical reassessment and laboratory monitoring are needed. Safety data at physiologic doses are not available beyond 24 months.

Do I need a blood test to know whether I need testosterone?

A blood testosterone value does not diagnose HSDD. Guidelines say there is no cutoff that separates women with and without sexual dysfunction. Testing is used to establish a baseline, avoid excessive exposure, and monitor treatment—not to turn low desire into a one-number diagnosis.

What is the difference between DHEA and testosterone for women?

DHEA is a precursor hormone; testosterone is the hormone itself. Systemic DHEA is not recommended by Global Consensus for postmenopausal HSDD. Vaginal prasterone is an FDA-approved local treatment for menopausal dyspareunia and is a different product for a different problem.

Is Addyi an FDA-approved needle-free alternative to testosterone?

For some women, yes. The current Addyi label covers women younger than 65 with acquired, generalized HSDD, including eligible postmenopausal women. It is not testosterone and has its own safety, interaction, dosing, and stop requirements. It belongs in the clinician conversation when the diagnosis fits.

Which telehealth providers prescribe testosterone to women?

In this six-provider check, Midi Health is the only clearly verified direct testosterone program. Winona does not prescribe testosterone; Sesame does not prescribe controlled substances online; Alloy does not offer it; Hers has testing but no treatment pathway we found; and Inner Balance publishes conflicting descriptions of whether Oestra contains testosterone.

---

Still not sure which HRT program is right for you? Take our free matching quiz.

Find My HRT Path

Get a personalized starting-point plan based on your symptoms, route preference, insurance, state, and the situations that belong with an in-person clinician first.

---

The HRT Index is an independent decision resource for online menopause and HRT care. We may earn a commission when readers start care through eligible provider links. That never changes the regulatory status of a medication, the route evidence, who a provider can serve, or what we publish when a provider's own pages conflict.

Primary sources and dated commercial sources

¹ U.S. Food and Drug Administration, Testosterone Information, updated June 23, 2026.

² Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019.

³ Parish SJ, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for HSDD in Women. 2021.

⁴ American College of Obstetricians and Gynecologists, Compounded Bioidentical Menopausal Hormone Therapy. 2023.

⁵ U.S. Food and Drug Administration, Menopause: compounded “bioidentical” hormones.

⁶ American College of Obstetricians and Gynecologists, Female Sexual Dysfunction Practice Bulletin summary. 2019.

⁷ U.S. Drug Enforcement Administration, Drug Scheduling.

⁸ American Society of Health-System Pharmacists, Testosterone Transdermal System—discontinued, March 13, 2023.

⁹ Pinto da Costa Viana D, et al. Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes. 2025.

¹⁰ Hernandez BS, et al. Long-term testosterone pellet insertion in women with low libido. 2025.

¹¹ European Medicines Agency, Intrinsa, authorization withdrawn May 25, 2012.

¹² U.S. National Library of Medicine, DailyMed testosterone gel 1.62% labeling.

¹³ U.S. Food and Drug Administration, FDA issues class-wide labeling changes for testosterone products, February 28, 2025.

¹⁴ Islam RM, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019.

¹⁵ U.S. National Library of Medicine, DailyMed Intrarosa prescribing information.

¹⁶ U.S. National Library of Medicine, DailyMed Addyi prescribing information.

¹⁷ U.S. National Library of Medicine, DailyMed Vyleesi prescribing information, updated November 13, 2025.

¹⁸ DEA and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, 90 Fed. Reg. 61301, December 31, 2025.

¹⁹ Midi Health, Testosterone Cream, checked August 17, 2026.

²⁰ Midi Health, Testosterone for women, checked August 17, 2026.

²¹ Midi Health, Testosterone for Menopause, checked August 17, 2026.

²² Midi Health, Cost of HRT, checked August 17, 2026.

²³ Winona, Why doesn't Winona prescribe testosterone?, checked August 17, 2026.

²⁴ Sesame Care, Online prescription refill visit, checked August 17, 2026.

²⁵ Hers, Free Testosterone, Female, checked August 17, 2026.

²⁶ Alloy, What role can testosterone play in menopause care?, checked August 17, 2026.

²⁷ Inner Balance, Oestra treatment page, checked August 17, 2026.

²⁸ Inner Balance, How to Boost Low Libido During Perimenopause, checked August 17, 2026.

²⁹ Midi Health, Pricing & Insurance, checked August 17, 2026.

³⁰ Midi Health, Terms and Conditions, updated July 23, 2026 and checked August 17, 2026.

³¹ U.S. National Library of Medicine, DailyMed Testopel prescribing information, updated July 17, 2025.

³² The Menopause Society, Statement on Misinformation Surrounding Hormone Therapy, accessed August 17, 2026.

³³ U.S. National Library of Medicine, DailyMed Natesto prescribing information, accessed August 17, 2026.